Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-03-27
1998-12-01
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514680, 514676, A61K 3112
Patent
active
058440046
ABSTRACT:
Therapeutic compositions comprising 1,8-dihyroxy-9(10H) anthracenones substituted at position 10 thereof with phenylalkylidene or arylacyl blocking moieties, said compounds having substantial therapeutic activity and minimal inflammatory effect.
REFERENCES:
patent: 4299846 (1981-11-01), Mustakallio et al.
patent: 4464301 (1984-08-01), Shroot et al.
patent: 4558069 (1985-12-01), Shroot et al.
patent: 4568743 (1986-02-01), Shroot et al.
patent: 4677123 (1987-06-01), Shroot et al.
patent: 4696941 (1987-09-01), Shroot et al.
patent: 4755530 (1988-07-01), Shroot et al.
patent: 4826996 (1989-05-01), Shroot et al.
patent: 4843097 (1989-06-01), Shroot et al.
patent: 4997961 (1991-03-01), Bruce
S. D. Brain et al., "Leukotriene B.sub.4 -like Material in Scale of Psoriatic Skin Lesions", British Journal of Pharmacology, 83, 1984, pp. 313-317.
E. A. Duell et al., "Determination of 5, 12, and 15-Lipoxygenase Products in Keratomed Biopsies of Normal and Psoriatic Skin", The Journal of Investigative Dermatology, 91(5), 1988, pp. 446-450.
K. Fogh et al., "Eicosanoids in Acute and Chronic Psoriatic Lesions: Leukotriene B.sub.4, but not 12-Hydroxy-Eicosatetraenoic Acid, is Present in Biologically Active Amounts in Acute Guttate Lesions", The Journal of Investigative Dermatology, 92(6), 1989, pp. 837-841.
J. Grabbe et al., "Identification of Chemotactic Lipoxygenase Products of Arachidonate Metabolism in Psoriatic Skin", The Journal of Investigative Dermatology, 82(5), 1984, pp. 477-479.
Jens-M. Schroder, "Anthralin (1,8-Dihydroxyanthrone) is a Potent Inhibitor of Leukotriene Production and LTB.sub.4 -.omega. Oxidation by Human Neutrophils", The Journal of Investigative Dermatology, 87(5), 1986, pp. 624-629.
G. Dannhardt and M. Lehr, "In-vitro Evaluation of 5-Lipoxygenase and Cyclo-oxygenase Inhibitors using Bovine Neutrophils and Platelets and HPLC", Journal of Pharmacy and Pharmacology, 44, 1992, pp. 419-424.
J. Fuchs et al., "Antioxidant and Prooxidant effects of the Antipsoriatic Compound: Anthralin in Skin and Subcellular Fractions", Antioxidants in Therapy and Preventive Medicine, I. Emerit et al., eds., Plenum Press, New York, NY, 1990, pp. 537-541.
A. Krebs et al., "Structure Specificity of the Antipsoriatic Anthrones", British Journal of Dermatology, 105(20), 1981, pp. 6-11.
R. F. Del Maestro, "Free Radical Injury During Inflamation", Free Radicals in Molecular Biology, Aging, and Disease, 27, D. Armstrong et al., eds., Raven Press, New York, NY, 1984, pp. 87-102.
K. Muller and H. Kappus, "Hydroxyl Radical Formation by Dithranol", Biochemical Pharmacology, 37(22), 1988, pp. 4277-4280.
L. Fry, "Psoriasis", British Journal of Dermatology, 119, 1988, pp. 445-461.
M. C. Venuti et al., "Topical Nonsteroidal Antipsoriatic Agents. 2. 2,3-(Alkylidenedioxy)naphthalene Analogues of Longapalene", Journal of Medicinal Chemistry, 31(11), 1988, pp. 2132-2136.
F. F. Hellier and M. Whitefield, "The Treatment of Psoriasis with Triacetoxyanthracene", The British Journal of Dermatology, 79(8-9), 1967, pp. 491-496.
P. Walstra et al., "Leukotriene Formation by Bovine Polymorphonuclear Leukocytes", Biochimica et Biophysica Acta, 795, 1984, pp. 499-503.
M. J. Finnen et al., "Inhibition of Dithranol Inflammation by Free-Radical Scavengers", The Lancet, II of 1984, pp. 1128-1130.
C. J. Bedord et al., "Anthralin Inhibition of Mouse Epidermal Arachidonic Acid Lipoxygenase in Vitro", The Journal of Investigative Dermatology, 81, 1983, pp. 566-571.
B. Kammerau et al., "Absolute Concentrations of Dithranol and Triacetyl-Dithranol in the Skin Layers After Local Treatment: In Vivo Investigations with Four Different Types of Pharmaceutical Vehicles", The Journal of Investigative Dermatology, 64, 1975, pp. 145-149.
K. K. Mustakallio, "Anthralin and Related Compounds Past, Present, and Future", Psoriasis, E. M. Farber et al., eds., Elsevier Science Publishing Co., Inc., New York, NY, 1986, pp. 172-180.
V. A. Ziboh et al. "Enhancement of 5-Lipoxygenase Activity in Soluble Preparations of Human Psoriatic Plaque Preparation", The Journal of Investigative Dermatology, Abstracts, Apr. 1983, p. 359.
K. D. Rainsford and B. P. Swann, "The Biochemistry and Pharmacology of Oxygen Radical Involvement in Eicosanoid Production", The Biology and Chemistry of Active Oxygen, J. V. Bannister and W. H. Bannister, eds., Elsevier Science Publishing Co., Inc., New York, NY, Chapter 5, 1984, pp. 105-127.
K. Muller et al., "Dithranol, Glucose-6-Phosphate Dehydrogenase Inhibition and Active Oxygen Species", Arzneimittel-Forschung Drug Research, 41, 1991, pp. 1113-1200.
B. Shroot and C. Brown, "Free Radicals in Skin Exposed to Dithranol and its Derivatives", Arzneimittel-Forschung Drug Research, 36, 1986, pp. 1253-1255.
W. Wiegrebe et al., "Dermal Absorption and Metabolism of the Antipsoriatic Drug Dithranol Triacetate", Arzneimittel-Forschung Drug Research, 34, 1984, pp. 48-51.
G. H. Jones et al., "Topical Nonsteroidal Antipsoriatic Agents. 1. 1,2,3,4-Tetraoxygenated Naphthalene Derivatives", Journal of Medicinal Chemistry, 29, 1986, pp. 1504-1511.
"Purification of Anthraquinone Derivatives", Chemical Abstracts, The American Chemical Society, 93(19), 1980, No. 93:204347.
K. Muller, "Active Oxygen Species and Structure Specificity of Antipsoriatic Anthrones", Archiv der Pharmazie, 321(7), 1988, pp. 385-389.
J. Taskinen et al., "Oxidation of Antipsoriatic 10-Acyldithranol Derivatives and Dithranol to 1,8-Dihyroxyanthraquinone", Archiv der Pharmazie, 321(2), 1988, pp. 103-106.
K. Muller et al., "Dithranol, Active Oxygen Species and Lipid Peroxidation in vivo", Archiv der Pharmazie, 320(1), 1987, pp. 59-66.
M. W. Greaves, "Irritation and Staining by 10-Butyryl Dithranol (Butantrone) in Psoriasis", International Journal of Clinical Pharmacology Research, VI(4), 1986, pp. 315-316.
B. H. Waksman, "Rationales of Current Therapies for Multiple Sclerosis", Archives of Neurology, 40, 1983, pp. 671-672.
R. M. McMillan and E. R. H. Walker, "Designing Therapeutically Effective 5-Lipoxygenase Inhibitors", The International Permaculture Solutions, 13, 1992, pp. 323-330.
L. Kemeny et al., "Dithranol: A Review of the Mechanism of Action in the Treatment of Psoriasis Vulgaris", Skin Pharmacology, 3, 1990, pp. 1-20.
A. B. Gottlieb et al., "Anthralin Decreases Keratinocyte TGF-.alpha. Expression and EGF-Receptor Binding In Vitro", The Journal of Investigative Dermatology, 98, 1992, pp. 680-685.
H. Brandt, "Antipsoriatic Activity of 10-Acyl Analoques of Dithranol (Anthralin)", Acta Derm. Venereol., 67, 1987, pp. 55-61.
B. Ramsey et al., "Reduction of Anthralin-Induced Inflammation by Application of Amines", Journal of the American Academy of Dermatology, 22, 1990, pp. 765-772.
H. Tanzer et al., "Anthralin Derivatives Inhibition of 5-Lipoxygenase Antipsoriatic Efficacy", Archiv der Pharmazie, 324, 1991, pp. 841-846.
A. Krebs et al., "Structure specificity of the anti-psoriatic anthrones," British Journal of Dermatology, 105, Supplement 20, 1981, pp. 6-11.
Jean-Daniel Berset et al., "Synthese und biochemische Eigenschaften von weiteren 10-Acylderivaten des Dithranols: Acetylsalicyldithranol und L-Acetyllaktyldithranol," Pharmaceutica Acta Helvetiae, 65, 1990, pp. 14-19 (English translation provided May 31, 1994).
Gurster Dieter
Muller Klaus
Peters, nee Piwek Susanne
Wiegrebe Wolfgang
Reamer James H.
Teva Pharmaceutical Industries Ltd.
LandOfFree
10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceutical will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2396125